December 09, 2025

Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved sevabertinib, an oral targeted therapy, for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (ERBB2) mut...

The ASCO Post

December 09, 2025

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surge...

The ASCO Post

December 05, 2025

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure

Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with...

The ASCO Post

December 05, 2025

European Society for Medical Oncology Congress 2025 Meeting Highlights

The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patient...

The ASCO Post

December 01, 2025

Dana-Farber Research News 12.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 - 15.

Dana-Farber

November 20, 2025

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.

Dana-Farber

November 19, 2025

Lung Cancer Treatment Evolutions Include Surgical Innovation and Molecular Targeted Therapy

Lung cancer survival rates have approximately doubled over the past two decades — a remarkable achievement driven by convergent advances in early detection, surgical technique and molecular oncology.

Baptist Health South Florida

November 19, 2025

Project ASCENT: Advancing Lung Cancer Screening in Hispanic Populations

Lung cancer remains the leading cause of cancer mortality in the United States, surpassing the combined deaths of breast, colon and prostate cancers.

Baptist Health South Florida

November 19, 2025

Expanding Treatment Options for Brain Metastases in NSCLC

Brain metastases in non-small cell lung cancer (NSCLC) have historically presented significant treatment challenges with limited options

Baptist Health South Florida